Skip to main content

Twin to Twin Transfusion Syndrome

0
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Fetoscopic Selective Laser PhotocoagulationN/A1 trial
Active Trials
NCT00345852Unknown150Est. May 2007
One Biosciences
One BiosciencesFrance - Paris
1 program
S-LPC:Selective Laser PhotocoagulationN/A1 trial
Active Trials
NCT02506049CompletedEst. Oct 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
One BiosciencesS-LPC:Selective Laser Photocoagulation
Human BioSciencesFetoscopic Selective Laser Photocoagulation

Clinical Trials (2)

Total enrollment: 150 patients across 2 trials

NCT02506049One BiosciencesS-LPC:Selective Laser Photocoagulation

Laser Photocoagulation in Twin to Twin Transfusion Syndrome

Start: Apr 2010Est. completion: Oct 2020
N/ACompleted
NCT00345852Human BioSciencesFetoscopic Selective Laser Photocoagulation

Fetoscopic Selective Laser Photocoagulation in Twin-Twin Transfusion Syndrome

Start: Mar 2002Est. completion: May 2007150 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.